Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data

Novartis’ radiopharmaceutical Pluvicto (lutetium Lu 177 vipivotide tetraxetan) met its primary endpoint in the Phase III PSMAfore trial, resulting in better radiographic progression-free survival in PSMA-positive patients with metastatic castration-resistant prostate cancer, the company announced Monday.